{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:19:44Z","timestamp":1792160384484,"version":"4.4.0"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T00:00:00Z","timestamp":1426550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1038\/nrclinonc.2015.38","type":"journal-article","created":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T13:29:24Z","timestamp":1426598964000},"page":"344-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":260,"title":["Genomics in acute lymphoblastic leukaemia: insights and treatment implications"],"prefix":"10.1038","volume":"12","author":[{"given":"Kathryn G.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,17]]},"reference":[{"key":"BFnrclinonc201538_CR1","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba, H., Greaves, M. & Mullighan, C. G. Acute lymphoblastic leukaemia. Lancet 381, 1943\u20131955 (2013).","journal-title":"Lancet"},{"key":"BFnrclinonc201538_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","volume":"28","author":"RH Ko","year":"2010","unstructured":"Ko, R. H. et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium Study. J. Clin. Oncol. 28, 648\u2013654 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/asheducation.V2012.1.129.3800156","volume":"2012","author":"EA Raetz","year":"2012","unstructured":"Raetz, E. A. & Bhatla, T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematology Am. Soc. Hematol. Educ. Program 2012, 129\u2013136 (2012).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"BFnrclinonc201538_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/asheducation-2010.1.21","volume":"2010","author":"W Stock","year":"2010","unstructured":"Stock, W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program. 2010, 21\u201329 (2010).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"BFnrclinonc201538_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.469","volume":"41","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. Rearrangement of CRLF2 in B-progenitor and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 41, 1243\u20131246 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758\u2013764 (2007).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110\u2013114 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470\u201380 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201538_CR9","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1073\/pnas.0811761106","volume":"106","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 106, 9414\u20139418 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201538_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature09727","volume":"471","author":"CG Mullighan","year":"2011","unstructured":"Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235\u2013239 (2011).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ng.2874","volume":"46","author":"E Papaemmanuil","year":"2014","unstructured":"Papaemmanuil, E. et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat. Genet. 46, 116\u2013125 (2014).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/sj.leu.2404691","volume":"21","author":"RP Kuiper","year":"2007","unstructured":"Kuiper, R. P. et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 21, 1258\u20131266 (2007).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR13","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1182\/blood-2013-05-500850","volume":"122","author":"A Perez-Garcia","year":"2013","unstructured":"Perez-Garcia, A. et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 122, 2425\u20132432 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2008-12-192039","volume":"114","author":"V Tosello","year":"2009","unstructured":"Tosello, V. et al. WT1 mutations in T-ALL. Blood 114, 1038\u20131045 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm.3078","volume":"19","author":"G Tzoneva","year":"2013","unstructured":"Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19, 368\u2013371 (2013).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201538_CR16","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1084\/jem.20112239","volume":"208","author":"P Van Vlierberghe","year":"2011","unstructured":"Van Vlierberghe, P. et al. ETV6 mutations in early immature human T cell leukemias. J. Exp. Med. 208, 2571\u20132579 (2011).","journal-title":"J. Exp. Med."},{"key":"BFnrclinonc201538_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ng.542","volume":"42","author":"P Van Vlierberghe","year":"2010","unstructured":"Van Vlierberghe, P. et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat. Genet. 42, 338\u2013342 (2010).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1182\/blood-2007-05-088310","volume":"111","author":"N Kawamata","year":"2008","unstructured":"Kawamata, N. et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 111, 776\u2013784 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157\u2013163 (2012).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242\u2013252 (2013).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","volume":"22","author":"KG Roberts","year":"2012","unstructured":"Roberts, K. G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22, 153\u2013166 (2012).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201538_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ng.2508","volume":"45","author":"K De Keersmaecker","year":"2013","unstructured":"De Keersmaecker, K. et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet. 45, 186\u2013190 (2013).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR23","doi-asserted-by":"publisher","first-page":"e1003997","DOI":"10.1371\/journal.pgen.1003997","volume":"9","author":"Z Kalender Atak","year":"2013","unstructured":"Kalender Atak, Z. et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 9, e1003997 (2013).","journal-title":"PLoS Genet."},{"key":"BFnrclinonc201538_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature13115","volume":"508","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508, 98\u2013102 (2014).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrg2841","volume":"11","author":"M Meyerson","year":"2010","unstructured":"Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685\u2013696 (2010).","journal-title":"Nat. Rev. Genet."},{"key":"BFnrclinonc201538_CR26","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1093\/hmg\/ddp396","volume":"18","author":"ER Mardis","year":"2009","unstructured":"Mardis, E. R. & Wilson, R. K. Cancer genome sequencing: a review. Hum. Mol. Genet. 18, R163\u2013R168 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrclinonc201538_CR27","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1056\/NEJMra1312543","volume":"370","author":"LG Biesecker","year":"2014","unstructured":"Biesecker, L. G. & Green, R. C. Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 370, 2418\u20132425 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201538_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cell.2014.05.049","volume":"158","author":"T Trimarchi","year":"2014","unstructured":"Trimarchi, T. et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell 158, 593\u2013606 (2014).","journal-title":"Cell"},{"key":"BFnrclinonc201538_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd4140","volume":"12","author":"H Ling","year":"2013","unstructured":"Ling, H., Fabbri, M. & Calin, G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847\u2013865 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrclinonc201538_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-biochem-051410-092902","volume":"81","author":"JL Rinn","year":"2012","unstructured":"Rinn, J. L. & Chang, H. Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 81, 145\u2013166 (2012).","journal-title":"Annu. Rev. Biochem."},{"key":"BFnrclinonc201538_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-genet-120213-092323","volume":"48","author":"R Bonasio","year":"2014","unstructured":"Bonasio, R. & Shiekhattar, R. Regulation of transcription by long noncoding RNAs. Annu. Rev. Genet. 48, 433\u2013455 (2014).","journal-title":"Annu. Rev. Genet."},{"key":"BFnrclinonc201538_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2013.06.020","volume":"154","author":"I Ulitsky","year":"2013","unstructured":"Ulitsky, I. & Bartel, D. P. lincRNAs: genomics, evolution, and mechanisms. Cell 154, 26\u201346 (2013).","journal-title":"Cell"},{"key":"BFnrclinonc201538_CR33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/nm.3665","volume":"20","author":"D Herranz","year":"2014","unstructured":"Herranz, D. et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat. Med. 20, 1130\u20131137 (2014).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201538_CR34","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1126\/science.1259037","volume":"346","author":"MR Mansour","year":"2014","unstructured":"Mansour, M. R. et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373\u20131377 (2014).","journal-title":"Science"},{"key":"BFnrclinonc201538_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2141.2008.07417.x","volume":"144","author":"CJ Harrison","year":"2009","unstructured":"Harrison, C. J. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br. J. Haematol. 144, 147\u2013156 (2009).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201538_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1468-0734.2002.00069.x","volume":"6","author":"CJ Harrison","year":"2002","unstructured":"Harrison, C. J. & Foroni, L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev. Clin. Exp. Hematol. 6, 91\u2013113 (2002).","journal-title":"Rev. Clin. Exp. Hematol."},{"key":"BFnrclinonc201538_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/gcc.20671","volume":"48","author":"K Paulsson","year":"2009","unstructured":"Paulsson, K. & Johansson, B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 48, 637\u2013660 (2009).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrclinonc201538_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2141.2004.04948.x","volume":"125","author":"CJ Harrison","year":"2004","unstructured":"Harrison, C. J. et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br. J. Haematol. 125, 552\u2013559 (2004).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201538_CR39","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2006-07-038299","volume":"110","author":"JB Nachman","year":"2007","unstructured":"Nachman, J. B. et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110, 1112\u20131115 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR40","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1002\/cncr.11841","volume":"98","author":"SC Raimondi","year":"2003","unstructured":"Raimondi, S. C. et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 98, 2715\u20132722 (2003).","journal-title":"Cancer"},{"key":"BFnrclinonc201538_CR41","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cll.2011.08.016","volume":"31","author":"CJ Harrison","year":"2011","unstructured":"Harrison, C. J. Acute lymphoblastic leukemia. Clin. Lab. Med. 31, 631\u2013647 (2011).","journal-title":"Clin. Lab. Med."},{"key":"BFnrclinonc201538_CR42","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","volume":"114","author":"LJ Russell","year":"2009","unstructured":"Russell, L. J. et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114, 2688\u20132698 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nri2304","volume":"8","author":"I Aifantis","year":"2008","unstructured":"Aifantis, I., Raetz, E. & Buonamici, S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat. Rev. Immunol. 8, 380\u2013390 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrclinonc201538_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.blre.2012.01.001","volume":"26","author":"AV Moorman","year":"2012","unstructured":"Moorman, A. V. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 26, 123\u2013135 (2012).","journal-title":"Blood Rev."},{"key":"BFnrclinonc201538_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fonc.2014.00054","volume":"4","author":"KM Bernt","year":"2014","unstructured":"Bernt, K. M. & Hunger, S. P. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front. Oncol. 4, 54 (2014).","journal-title":"Front. Oncol."},{"key":"BFnrclinonc201538_CR46","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman, A. V. et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109, 3189\u20133197 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 10, 125\u2013134 (2009).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201538_CR48","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2013-07-515148","volume":"122","author":"KG Roberts","year":"2013","unstructured":"Roberts, K. G. et al. Integrated genomic and mutational profiling of adolescent and young adult ALL Identifies a high frequency of BCR-ABL1-like ALL cases with very poor outcome [abstract]. Blood 122, 825 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR49","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005\u20131015 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201538_CR50","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1053\/j.seminhematol.2013.10.001","volume":"50","author":"CG Mullighan","year":"2013","unstructured":"Mullighan, C. G. Genomic characterization of childhood acute lymphoblastic leukemia. Semin. Hematol. 50, 314\u2013324 (2013).","journal-title":"Semin. Hematol."},{"key":"BFnrclinonc201538_CR51","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377\u20131380 (2008).","journal-title":"Science"},{"key":"BFnrclinonc201538_CR52","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1182\/blood-2008-06-165027","volume":"112","author":"JJ Yang","year":"2008","unstructured":"Yang, J. J. et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112, 4178\u20134183 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR53","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3892\/ijo_00000290","volume":"34","author":"N Kawamata","year":"2009","unstructured":"Kawamata, N. et al. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int. J. Oncol. 34, 1603\u20131612 (2009).","journal-title":"Int. J. Oncol."},{"key":"BFnrclinonc201538_CR54","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/leu.2012.227","volume":"27","author":"S Safavi","year":"2013","unstructured":"Safavi, S. et al. Loss of chromosomes is the primary event in near-haploid and low-hypodiploid acute lymphoblastic leukemia. Leukemia 27, 248\u2013250 (2013).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR55","unstructured":"Ma, X. et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-progenitor acute lymphoblastic leukemia. Nat. Commun. (in press)."},{"key":"BFnrclinonc201538_CR56","doi-asserted-by":"publisher","unstructured":"Andersson, A. K. et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukaemias. Nat. Genet. http:\/\/dx.doi.org\/10.1038\/ng.3230 .","DOI":"10.1038\/ng.3230"},{"key":"BFnrclinonc201538_CR57","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2010.63","volume":"24","author":"C Virely","year":"2010","unstructured":"Virely, C. et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 24, 1200\u20131204 (2010).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR58","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V112.11.1789.1789","volume":"112","author":"J Dang","year":"2008","unstructured":"Dang, J., Mullighan, C. G., Phillips, L. A., Mehta, P. & Downing, J. R. Retroviral and chemical mutagenesis Identifies Pax5 as a tumor suppressor in B-progenitor acute lymphoblastic leukemia. Blood 112, 1789 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR59","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/ni.2707","volume":"14","author":"H Schjerven","year":"2013","unstructured":"Schjerven, H. et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat. Immunol. 14, 1073\u20131083 (2013).","journal-title":"Nat. Immunol."},{"key":"BFnrclinonc201538_CR60","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/ni.2821","volume":"15","author":"I Joshi","year":"2014","unstructured":"Joshi, I. et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat. Immunol. 15, 294\u2013304 (2014).","journal-title":"Nat. Immunol."},{"key":"BFnrclinonc201538_CR61","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/44076","volume":"401","author":"SL Nutt","year":"1999","unstructured":"Nutt, S. L., Heavey, B., Rolink, A. G. & Busslinger, M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556\u2013562 (1999).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR62","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1158\/1541-7786.MCR-13-0337","volume":"12","author":"K Fortschegger","year":"2014","unstructured":"Fortschegger, K., Anderl, S., Denk, D. & Strehl, S. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development. Mol. Cancer Res. 12, 595\u2013606 (2014).","journal-title":"Mol. Cancer Res."},{"key":"BFnrclinonc201538_CR63","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/onc.2011.291","volume":"31","author":"N Kawamata","year":"2012","unstructured":"Kawamata, N., Pennella, M. A., Woo, J. L., Berk, A. J. & Koeffler, H. P. Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene 31, 966\u2013977 (2012).","journal-title":"Oncogene"},{"key":"BFnrclinonc201538_CR64","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/leu.2008.306","volume":"23","author":"K Nebral","year":"2009","unstructured":"Nebral, K. et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23, 134\u2013143 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR65","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1101\/gad.240416.114","volume":"28","author":"GJ Liu","year":"2014","unstructured":"Liu, G. J. et al. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. Genes Dev. 28, 1337\u20131350 (2014).","journal-title":"Genes Dev."},{"key":"BFnrclinonc201538_CR66","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/ni.2828","volume":"15","author":"TA Schwickert","year":"2014","unstructured":"Schwickert, T. A. et al. Stage-specific control of early B cell development by the transcription factor Ikaros. Nat. Immunol. 15, 283\u2013293 (2014).","journal-title":"Nat. Immunol."},{"key":"BFnrclinonc201538_CR67","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/blood.V122.21.172.172","volume":"122","author":"M Churchman","year":"2013","unstructured":"Churchman, M. et al. High content screening identifies synthetic lethality of retinoid receptor agonists in IKZF1-mutated BCR-ABL1 positive acute lymphoblastic leukemia. Blood 122, 172 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR68","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","volume":"123","author":"A van der Veer","year":"2014","unstructured":"van der Veer, A. et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 123, 1691\u20131698 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR69","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","volume":"115","author":"RC Harvey","year":"2010","unstructured":"Harvey, R. C. et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115, 5312\u20135321 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR70","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503\u2013514 (2012).","journal-title":"Immunity"},{"key":"BFnrclinonc201538_CR71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/gcc.20502","volume":"47","author":"K Paulsson","year":"2008","unstructured":"Paulsson, K. et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 47, 26\u201333 (2008).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrclinonc201538_CR72","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bcmd.2010.07.007","volume":"45","author":"JL Wiemels","year":"2010","unstructured":"Wiemels, J. L. et al. Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia. Blood Cells Mol. Dis. 45, 186\u2013191 (2010).","journal-title":"Blood Cells Mol. Dis."},{"key":"BFnrclinonc201538_CR73","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","volume":"124","author":"J Irving","year":"2014","unstructured":"Irving, J. et al. Ras pathway mutations are highly prevalent in relapsed childhood acute lymphoblastic leukaemia, may act as relapse-drivers and confer sensitivity to MEK inhibition. Blood 124, 3420\u20133430 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR74","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","volume":"122","author":"A van der Veer","year":"2013","unstructured":"van der Veer, A. et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122, 2622\u20132629 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR75","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","volume":"121","author":"ML Loh","year":"2013","unstructured":"Loh, M. L. et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood 121, 485\u2013488 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR76","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood.V122.21.352.352","volume":"112","author":"N Kiyokawa","year":"2013","unstructured":"Kiyokawa, N. et al. An analysis of Ph-like ALL in Japanese patients [abstract]. Blood 112, 352 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR77","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","volume":"360","author":"CH Pui","year":"2009","unstructured":"Pui, C. H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730\u20132741 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201538_CR78","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","volume":"32","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J. Clin. Oncol. 32, 3012\u20133020 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR79","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","volume":"31","author":"BW Weston","year":"2013","unstructured":"Weston, B. W. et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J. Clin. Oncol. 31, e413\u2013e416 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR80","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","volume":"98","author":"E Lengline","year":"2013","unstructured":"Lengline, E. et al. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 98, e146\u2013e148 (2013).","journal-title":"Haematologica"},{"key":"BFnrclinonc201538_CR81","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","volume":"27","author":"KR Schultz","year":"2009","unstructured":"Schultz, K. R. et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J. Clin. Oncol. 27, 5175\u20135181 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR82","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.V122.21.826.826","volume":"122","author":"RC Harvey","year":"2013","unstructured":"Harvey, R. C. et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a philadelphia chromosome-like (\u201cPh-like\u201d or \u201cBCR-ABL1-Like\u201d) signature for therapeutic targeting and clinical intervention [abstract]. Blood 122, 826 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR83","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","volume":"115","author":"L Hertzberg","year":"2010","unstructured":"Hertzberg, L. et al. Down syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the iBFM Study Group. Blood 115, 1006\u20131017 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR84","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1038\/leu.2012.84","volume":"26","author":"TD Buitenkamp","year":"2012","unstructured":"Buitenkamp, T. D. et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 26, 2204\u20132211 (2012).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR85","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0911726107","volume":"107","author":"A Yoda","year":"2010","unstructured":"Yoda, A. et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 107, 252\u2013257 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201538_CR86","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1182\/blood-2013-10-529685","volume":"124","author":"C Shochat","year":"2014","unstructured":"Shochat, C. et al. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood 124, 106\u2013110 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR87","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1182\/blood-2009-11-256131","volume":"115","author":"G Cario","year":"2010","unstructured":"Cario, G. et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115, 5393\u20135397 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR88","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1038\/leu.2012.101","volume":"10","author":"C Palmi","year":"2012","unstructured":"Palmi, C. et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 10, 2245\u20132253 (2012).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR89","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/pbc.24571","volume":"60","author":"Y Yamashita","year":"2013","unstructured":"Yamashita, Y. et al. IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatr. Blood Cancer 60, 1587\u20131592 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc201538_CR90","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09221.x","volume":"158","author":"A Attarbaschi","year":"2012","unstructured":"Attarbaschi, A. et al. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. Br. J. Haematol. 158, 772\u2013777 (2012).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201538_CR91","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","volume":"119","author":"IM Chen","year":"2012","unstructured":"Chen, I. M. et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 119, 3512\u20133522 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR92","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1182\/blood-2010-07-297135","volume":"117","author":"HM Ensor","year":"2011","unstructured":"Ensor, H. M. et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 117, 2129\u20132136 (2011).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR93","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","volume":"372","author":"D Bercovich","year":"2008","unstructured":"Bercovich, D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 1484\u20131492 (2008).","journal-title":"Lancet"},{"key":"BFnrclinonc201538_CR94","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1038\/ncomms5654","volume":"5","author":"SI Nikolaev","year":"2014","unstructured":"Nikolaev, S. I. et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat. Commun. 5, 4654 (2014).","journal-title":"Nat. Commun."},{"key":"BFnrclinonc201538_CR95","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","volume":"120","author":"SK Tasian","year":"2012","unstructured":"Tasian, S. K. et al. Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 120, 833\u2013842 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR96","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","volume":"120","author":"SL Maude","year":"2012","unstructured":"Maude, S. L. et al. Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120, 3510\u20133518 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR97","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1084\/jem.20110580","volume":"208","author":"C Shochat","year":"2011","unstructured":"Shochat, C. et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208, 901\u2013908 (2011).","journal-title":"J. Exp. Med."},{"key":"BFnrclinonc201538_CR98","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/ng.924","volume":"43","author":"PP Zenatti","year":"2011","unstructured":"Zenatti, P. P. et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 43, 932\u2013939 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR99","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1084\/jem.20122727","volume":"211","author":"LM Treanor","year":"2014","unstructured":"Treanor, L. M. et al. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J. Exp. Med. 211, 701\u2013713 (2014).","journal-title":"J. Exp. Med."},{"key":"BFnrclinonc201538_CR100","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1182\/blood.V75.5.1170.1170","volume":"75","author":"CH Pui","year":"1990","unstructured":"Pui, C. H. et al. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood 75, 1170\u20131177 (1990).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood.V70.1.247.247","volume":"70","author":"CH Pui","year":"1987","unstructured":"Pui, C. H. et al. Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood 70, 247\u2013253 (1987).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR102","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1073\/pnas.0803494105","volume":"105","author":"Q An","year":"2008","unstructured":"An, Q. et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc. Natl Acad. Sci. USA 105, 17050\u201317054 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201538_CR103","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/gcc.22163","volume":"53","author":"V Muhlbacher","year":"2014","unstructured":"Muhlbacher, V. et al. Acute lymphoblastic leukemia with low hypodiploid\/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 53, 524\u2013536 (2014).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrclinonc201538_CR104","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V110.11.691.691","volume":"110","author":"CG Mullighan","year":"2007","unstructured":"Mullighan, C. G. et al. ERG deletions define a novel subtype of B-progenitor acute lymphoblastic leukemia [abstract]. Blood 110, 691 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR105","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644\u2013648 (2005).","journal-title":"Science"},{"key":"BFnrclinonc201538_CR106","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1200\/JCO.2007.10.8720","volume":"25","author":"G Marcucci","year":"2007","unstructured":"Marcucci, G. et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 25, 3337\u20133343 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR107","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/leu.2013.277","volume":"28","author":"E Clappier","year":"2014","unstructured":"Clappier, E. et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28, 70\u201377 (2014).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR108","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1182\/blood-2006-08-040436","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman, A. V. et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109, 2327\u20132330 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR109","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/leu.2013.317","volume":"28","author":"CJ Harrison","year":"2014","unstructured":"Harrison, C. J. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28, 1015\u20131021 (2014).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR110","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1200\/JCO.2013.49.1308","volume":"31","author":"NA Heerema","year":"2013","unstructured":"Heerema, N. A. et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the Children's Oncology Group. J. Clin. Oncol. 31, 3397\u20133402 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR111","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1200\/JCO.2013.48.9377","volume":"31","author":"AV Moorman","year":"2013","unstructured":"Moorman, A. V. et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97\/99 and UKALL2003 trials. J. Clin. Oncol. 31, 3389\u20133396 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR112","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269\u2013271 (2004).","journal-title":"Science"},{"key":"BFnrclinonc201538_CR113","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1084\/jem.20070876","volume":"204","author":"J O'Neil","year":"2007","unstructured":"O'Neil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204, 1813\u20131824 (2007).","journal-title":"J. Exp. Med."},{"key":"BFnrclinonc201538_CR114","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"A Gutierrez","year":"2009","unstructured":"Gutierrez, A. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647\u2013650 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR115","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm1636","volume":"13","author":"T Palomero","year":"2007","unstructured":"Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13, 1203\u20131210 (2007).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201538_CR116","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith, E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147\u2013156 (2009).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201538_CR117","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1038\/bcj.2011.49","volume":"2","author":"M Neumann","year":"2012","unstructured":"Neumann, M. et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2, e55 (2012).","journal-title":"Blood Cancer J."},{"key":"BFnrclinonc201538_CR118","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","volume":"156","author":"T Inukai","year":"2012","unstructured":"Inukai, T. et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99\u201315 Br. J. Haematol. 156, 358\u2013365 (2012).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201538_CR119","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjh.12882","volume":"166","author":"K Patrick","year":"2014","unstructured":"Patrick, K. et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br. J. Haematol. 166, 421\u2013424 (2014).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201538_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2014-05-575407","volume":"124","author":"BL Wood","year":"2014","unstructured":"Wood, B. L. et al. T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children's Oncology Group (COG) study AALL0434 [abstract]. Blood 124, 1 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR121","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.2651","volume":"18","author":"P Ntziachristos","year":"2012","unstructured":"Ntziachristos, P. et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298\u2013303 (2012).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201538_CR122","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nm.2610","volume":"18","author":"G Della Gatta","year":"2012","unstructured":"Della Gatta, G. et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat. Med. 18, 436\u2013440 (2012).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201538_CR123","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3324\/haematol.2012.064485","volume":"97","author":"L Yan","year":"2012","unstructured":"Yan, L. et al. Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica 97, 1708\u20131712 (2012).","journal-title":"Haematologica"},{"key":"BFnrclinonc201538_CR124","doi-asserted-by":"publisher","first-page":"e1003997","DOI":"10.1371\/journal.pgen.1003997","volume":"9","author":"ZK Atak","year":"2013","unstructured":"Atak, Z. K. et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 9, e1003997 (2013).","journal-title":"PLoS Genet."},{"key":"BFnrclinonc201538_CR125","doi-asserted-by":"publisher","first-page":"18261","DOI":"10.1073\/pnas.0606108103","volume":"103","author":"T Palomero","year":"2006","unstructured":"Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261\u201318266 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201538_CR126","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1172\/JCI66203","volume":"123","author":"ME Figueroa","year":"2013","unstructured":"Figueroa, M. E. et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J. Clin. Invest. 123, 3099\u20133111 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201538_CR127","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/2159-8290.CD-12-0208","volume":"2","author":"H Geng","year":"2012","unstructured":"Geng, H. et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2, 1004\u20131023 (2012).","journal-title":"Cancer Discov."},{"key":"BFnrclinonc201538_CR128","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2009-04-214668","volume":"115","author":"L Milani","year":"2010","unstructured":"Milani, L. et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115, 1214\u20131225 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR129","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1182\/blood-2009-09-243634","volume":"115","author":"E Schafer","year":"2010","unstructured":"Schafer, E. et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood 115, 4798\u20134809 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR130","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1158\/0008-5472.CAN-05-4418","volume":"66","author":"I Airoldi","year":"2006","unstructured":"Airoldi, I. et al. Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res. 66, 3978\u20133980 (2006).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201538_CR131","first-page":"832","volume":"57","author":"A Batova","year":"1997","unstructured":"Batova, A. et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 57, 832\u2013836 (1997).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201538_CR132","doi-asserted-by":"publisher","first-page":"e65373","DOI":"10.1371\/journal.pone.0065373","volume":"8","author":"M Borssen","year":"2013","unstructured":"Borssen, M. et al. Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS ONE 8, e65373 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc201538_CR133","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/sj.leu.2401437","volume":"13","author":"M Nakamura","year":"1999","unstructured":"Nakamura, M. et al. p16\/MTS1\/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. Leukemia 13, 884\u2013890 (1999).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR134","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1365-2141.2008.07523.x","volume":"144","author":"K Paulsson","year":"2009","unstructured":"Paulsson, K. et al. Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia. Br. J. Haematol. 144, 838\u2013847 (2009).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201538_CR135","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1182\/blood-2004-03-0954","volume":"104","author":"J Roman-Gomez","year":"2004","unstructured":"Roman-Gomez, J. et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104, 2492\u20132498 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR136","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","volume":"114","author":"DJ Stumpel","year":"2009","unstructured":"Stumpel, D. J. et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 114, 5490\u20135498 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR137","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/leu.2010.282","volume":"25","author":"DJ Stumpel","year":"2011","unstructured":"Stumpel, D. J. et al. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia 25, 429\u2013439 (2011).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR138","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1158\/0008-5472.CAN-06-3993","volume":"67","author":"KH Taylor","year":"2007","unstructured":"Taylor, K. H. et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 67, 2617\u20132625 (2007).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201538_CR139","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.leukres.2005.06.002","volume":"30","author":"Y Yang","year":"2006","unstructured":"Yang, Y. et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk. Res. 30, 98\u2013102 (2006).","journal-title":"Leuk. Res."},{"key":"BFnrclinonc201538_CR140","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","volume":"17","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13\u201327 (2010).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201538_CR141","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/ng.2777","volume":"45","author":"JD Jaffe","year":"2013","unstructured":"Jaffe, J. D. et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45, 1386\u20131391 (2013).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR142","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1038\/ncomms4469","volume":"5","author":"BG Mar","year":"2014","unstructured":"Mar, B. G. et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat. Commun. 5, 3469 (2014).","journal-title":"Nat. Commun."},{"key":"BFnrclinonc201538_CR143","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ng.2913","volume":"46","author":"B Knoechel","year":"2014","unstructured":"Knoechel, B. et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 46, 364\u2013370 (2014).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR144","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","volume":"123","author":"JE Roderick","year":"2014","unstructured":"Roderick, J. E. et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123, 1040\u20131050 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR145","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature13605","volume":"514","author":"P Ntziachristos","year":"2014","unstructured":"Ntziachristos, P. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513\u2013517 (2014).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR146","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/brain\/118.5.1087","volume":"118","author":"KP Bhatia","year":"1995","unstructured":"Bhatia, K. P. et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 118, 1087\u20131093 (1995).","journal-title":"Brain"},{"key":"BFnrclinonc201538_CR147","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.2011.34.8144","volume":"29","author":"J Hof","year":"2011","unstructured":"Hof, J. et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 29, 3185\u20133193 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR148","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ng.2558","volume":"45","author":"JA Meyer","year":"2013","unstructured":"Meyer, J. A. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45, 290\u2013294 (2013).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR149","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham, M. et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120, 5173\u20135180 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR150","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/gm524","volume":"6","author":"BJ Raphael","year":"2014","unstructured":"Raphael, B. J., Dobson, J. R., Oesper, L. & Vandin, F. Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med. 6, 5 (2014).","journal-title":"Genome Med."},{"key":"BFnrclinonc201538_CR151","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR152","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nmeth.2891","volume":"11","author":"V Marx","year":"2014","unstructured":"Marx, V. Cancer genomes: discerning drivers from passengers. Nat. Meth. 11, 375\u2013379 (2014).","journal-title":"Nat. Meth."},{"key":"BFnrclinonc201538_CR153","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR154","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","DOI":"10.1038\/ng.2764"},{"key":"BFnrclinonc201538_CR155","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714\u2013726 (2013).","journal-title":"Cell"},{"key":"BFnrclinonc201538_CR156","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/jnci\/djt042","volume":"105","author":"H Xu","year":"2013","unstructured":"Xu, H. et al. Novel susceptibility variants at 10p12.31\u2013122 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J. Natl Cancer Inst. 105, 733\u2013742 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201538_CR157","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/ng.2803","volume":"45","author":"V Perez-Andreu","year":"2013","unstructured":"Perez-Andreu, V. et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. 45, 1494\u20131498 (2013).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR158","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1182\/blood-2012-07-440107","volume":"120","author":"JJ Yang","year":"2012","unstructured":"Yang, J. J. et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 120, 4197\u20134204 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR159","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/ng.763","volume":"43","author":"JJ Yang","year":"2011","unstructured":"Yang, J. J. et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat. Genet. 43, 237\u2013241 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR160","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/leu.2009.277","volume":"24","author":"W Yang","year":"2010","unstructured":"Yang, W. et al. ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia 24, 894\u2013896 (2010).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR161","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jama.2009.7","volume":"301","author":"JJ Yang","year":"2009","unstructured":"Yang, J. J. et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301, 393\u2013403 (2009).","journal-title":"JAMA"},{"key":"BFnrclinonc201538_CR162","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/ng.432","volume":"41","author":"LR Trevino","year":"2009","unstructured":"Trevino, L. R. et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1001\u20131005 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR163","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1182\/blood-2013-03-491316","volume":"122","author":"G Migliorini","year":"2013","unstructured":"Migliorini, G. et al. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood 122, 3298\u20133307 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR164","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ng.585","volume":"42","author":"AL Sherborne","year":"2010","unstructured":"Sherborne, A. L. et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat. Genet. 42, 492\u2013494 (2010).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR165","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1182\/blood-2009-09-241513","volume":"115","author":"RB Prasad","year":"2010","unstructured":"Prasad, R. B. et al. Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood 115, 1765\u20131767 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR166","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.430","volume":"41","author":"E Papaemmanuil","year":"2009","unstructured":"Papaemmanuil, E. et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1006\u20131010 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR167","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/ng.2754","volume":"45","author":"S Shah","year":"2013","unstructured":"Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226\u20131231 (2013).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201538_CR168","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/pbc.24417","volume":"60","author":"BC Powell","year":"2013","unstructured":"Powell, B. C. et al. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr. Blood Cancer 60, E1\u2013E3 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc201538_CR169","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2009-09-235986","volume":"115","author":"MJ Dyer","year":"2009","unstructured":"Dyer, M. J. et al. Immunoglobulin heavy chain (IGH) locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL): rare clinical curios or potent genetic drivers? Blood 115, 1490\u20131499 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR170","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2014-09-595744","volume":"125","author":"V Perez-Andreu","year":"2015","unstructured":"Perez-Andreu, V. et al. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 125, 680\u2013686 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR171","first-page":"1136","volume":"5","author":"F Auer","year":"2013","unstructured":"Auer, F. et al. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A. Leukemia 5, 1136\u20131138 (2013).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR172","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","volume":"29","author":"CH Pui","year":"2011","unstructured":"Pui, C. H., Carroll, W. L., Meshinchi, S. & Arceci, R. J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29, 551\u2013565 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR173","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/MOH.0b013e3283543d5c","volume":"19","author":"D Campana","year":"2012","unstructured":"Campana, D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr. Opin. Hematol. 19, 313\u2013318 (2012).","journal-title":"Curr. Opin. Hematol."},{"key":"BFnrclinonc201538_CR174","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/leu.2010.275","volume":"25","author":"E Waanders","year":"2011","unstructured":"Waanders, E. et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 25, 254\u2013258 (2011).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR175","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/leu.2010.87","volume":"24","author":"RP Kuiper","year":"2010","unstructured":"Kuiper, R. P. et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 24, 1258\u20131264 (2010).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR176","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.3324\/haematol.2013.099077","volume":"98","author":"C Palmi","year":"2013","unstructured":"Palmi, C. et al. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to \u201cincidence and biological significance of IKZF1\/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia\u201d. Haematologica 98, e164\u2013e165 (2013).","journal-title":"Haematologica"},{"key":"BFnrclinonc201538_CR177","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3324\/haematol.2012.075432","volume":"98","author":"C Palmi","year":"2013","unstructured":"Palmi, C. et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica 98, 1226\u20131231 (2013).","journal-title":"Haematologica"},{"key":"BFnrclinonc201538_CR178","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","volume":"14","author":"D Bhojwani","year":"2013","unstructured":"Bhojwani, D. & Pui, C. H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 14, e205\u2013e217 (2013).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201538_CR179","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/leu.2011.348","volume":"26","author":"NC Venn","year":"2012","unstructured":"Venn, N. C. et al. Highly sensitive MRD tests for ALL based on the IKZF1 Delta3\u20136 microdeletion. Leukemia 26, 1414\u20131416 (2012).","journal-title":"Leukemia"},{"key":"BFnrclinonc201538_CR180","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1586\/ehm.13.28","volume":"6","author":"JA Meyer","year":"2013","unstructured":"Meyer, J. A., Carroll, W. L. & Bhatla, T. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia? Expert. Rev. Hematol. 6, 223\u2013224 (2013).","journal-title":"Expert. Rev. Hematol."},{"key":"BFnrclinonc201538_CR181","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","volume":"114","author":"I Iacobucci","year":"2009","unstructured":"Iacobucci, I. et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114, 2159\u20132167 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR182","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","volume":"27","author":"G Martinelli","year":"2009","unstructured":"Martinelli, G. et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J. Clin. Oncol. 27, 5202\u20135207 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201538_CR183","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1365-2141.2008.07552.x","volume":"144","author":"A Gaikwad","year":"2009","unstructured":"Gaikwad, A. et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br. J. Haematol. 144, 930\u2013932 (2009).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201538_CR184","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood-2008-08-170928","volume":"113","author":"L Kearney","year":"2008","unstructured":"Kearney, L. et al. A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukaemia. Blood 113, 646\u2013648 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201538_CR185","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0911726107","volume":"107","author":"A Yoda","year":"2010","unstructured":"Yoda, A. et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 107, 252\u2013257 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201538_CR186","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature09730","volume":"471","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189\u2013195 (2011).","journal-title":"Nature"},{"key":"BFnrclinonc201538_CR187","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0145-2126(97)80032-X","volume":"21","author":"O Blau","year":"1997","unstructured":"Blau, O. et al. Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia. Leuk. Res. 21, 721\u2013729 (1997).","journal-title":"Leuk. Res."},{"key":"BFnrclinonc201538_CR188","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00043426-200110000-00005","volume":"23","author":"J Gump","year":"2001","unstructured":"Gump, J., McGavran, L., Wei, Q. & Hunger, S. P. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 23, 416\u2013469 (2001).","journal-title":"J. Pediatr. Hematol. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.38","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:28:55Z","timestamp":1684466935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2015.38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,17]]},"references-count":188,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["BFnrclinonc201538"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2015.38","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,17]]},"assertion":[{"value":"17 March 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}